In this CME Outfitters Journal Club, expert faculty will provide their perspectives on key aspects of the FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. Focus will be on bringing the concepts from this document into daily practice including strategies for identifying the physiologic biopsychosocial factors that influence pain, utilizing pain assessment tools that reinforce approaches to the appropriate management of pain, implementing strategies from the 2022 CDC Guideline for Prescribing Opioids into the development of safe and effective pain management plans, and other valuable skills for improving the treatment of patients suffering from chronic pain.
This CMEO Journal Club will equip HCPs with the latest evidence from recent clinical trials and scientific literature, enabling them to evaluate new prophylactic strategies and incorporate non-factor therapies into comprehensive, individualized treatment plans. Expert faculty will translate data into real-world insights to support improved patient outcomes and long-term disease management.
Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.
In this CMEO Journal Club, expert faculty will present and discuss the very latest research abstracts from the American Academy of Neurology (AAN) 2025 Annual Meeting and the Associated Professional Sleep Societies (APSS) SLEEP 2025 Annual Meeting, including the latest information on psychiatric and CV/CM comorbidities for patients living with IH and narcolepsy, the impact of these comorbidities on patients’ QoL, and how to customize treatment that mitigates risk.
In this CME Outfitters Journal Club, expert faculty will present and discuss the very latest research on international diagnostic and treatment guidelines as well as clinical trial data from published abstracts on the latest treatment options for CIDP.
In this CME Outfitters Journal Club, expert faculty will present and discuss the very latest research abstracts from the 2024 Peripheral Nerve Society Annual Meeting (June 2024), including the latest research on the role of the complement system in CIPD, clinical and electrophysical variants of CIDP, and standard vs. emerging treatment options for CIDP.
